Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 14, 2025 08:30 ET | Source: Ernexa Therapeutics Inc.

Ernexa Therapeutics Establishes Texas Subsidiary to Support Continued Development of ERNA-101 and Future Clinical Operations

CAMBRIDGE, Mass., May 14, 2025 (GLOBE NEWSWIRE) -- Ernexa Therapeutics (Nasdaq: ERNA), developing innovative cell therapies for the treatment of advanced cancer and autoimmune disease, today...
March 25, 2025 08:30 ET | Source: Ernexa Therapeutics

Eterna Therapeutics Changes Name to Ernexa Therapeutics to Reflect New Strategic Focus on Ovarian Cancer and Autoimmune Disease

Ernexa Therapeutics embarks on new strategic direction, shifting the company’s focus from delivering a cell therapy platform to prioritizing product development New tagline to emphasize the company’s...
January 28, 2025 08:30 ET | Source: Eterna Therapeutics

Eterna Therapeutics Announces Expansion of Scientific Advisory Board

CAMBRIDGE, Mass., Jan. 28, 2025 (GLOBE NEWSWIRE) -- Eterna Therapeutics (Nasdaq: ERNA), a leader in cell therapies for the treatment of advanced solid tumors, today announced the addition of Jerome...
November 14, 2024 16:40 ET | Source: HCW Biologics, Inc

HCW Biologics Reports Third Quarter 2024 Financial Results and Business Highlights

Press release for Q3 2024 business highlights and financial results
August 23, 2024 16:30 ET | Source: HCW Biologics, Inc

HCW Biologics Reports Second Quarter 2024 Financial Results and Business Highlights - Correction

Results of Q2 2024, including settlement of long-running arbitration.
August 14, 2024 16:35 ET | Source: HCW Biologics, Inc

HCW Biologics Reports Second Quarter 2024 Financial Results and Business Highlights

Results of Q2 2024, including settlement of long-running arbitration.
December 07, 2022 07:30 ET | Source: HCW Biologics, Inc

HCW Biologics is Granted Second Fundamental Patent: U.S. Patent for Multi-Chain Chimeric Polypeptide Created with TOBI™ Platform

Allowed Claims for Novel Immunotherapeutic Compound Constructed with Tissue Factor as Platform for Target Binding Domains Patent for Underlying Intellectual Property for HCW9218 Currently in Clinical...
August 24, 2021 07:32 ET | Source: HCW Biologics, Inc

HCW Biologics Showcases Scientific Paper in Molecular Therapy Highlighting Potential of HCW9218 as Novel, Bifunctional Cancer Immunotherapeutic

Lead Drug Candidate Engineered Using Tissue FactOr-Based FusIon (TOBI™) Platform Preclinical Data Demonstrated HCW9218 Antitumor Activity as Single-Agent Monotherapy and as an Adjunct to Enhance...
August 17, 2021 07:32 ET | Source: HCW Biologics, Inc

HCW Biologics’ Article Published in Cancer Immunology Research Validates Novel Tissue Factor Scaffold Fusion Protein (TOBI™) Discovery Platform

TOBI™ Discovery Platform Creates GMP-Scale Heteromeric Fusion Protein Complexes (HFPCs) That Solve Issues with Multi-Signal Receptor Engagement on Immune Cells MIRAMAR, Fla., Aug. 17, 2021 (GLOBE...
August 13, 2021 07:10 ET | Source: HCW Biologics, Inc

HCW Biologics Reports Second Quarter Financial Results and Recent Business Highlights

MIRAMAR, Fla., Aug. 13, 2021 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the “Company”) (NASDAQ: HCWB), an innovative, biopharmaceutical company focused on discovering and developing novel...